drugset / Trial / NCT04576910
Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China
Phase 4
Completed
387 enrolled
Zhejiang Provincial Center for Disease Control and Prevention
China National Biotec Group Company Limited · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This study is to evaluate the immunogenicity and safety of Sabin IPV or bOPV, given as a booster vaccination in children aged 4 years who were previously immunised with different sequential immunization history by Sabin IPV and bOPV, and to observe the antibody persistence three years after different primary sequential immunization with Sabin IPV or bOPV at age 2, 3 and 4 months.
Timeline
- Start
- 2020-11-05
- Primary completion
- 2021-06-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sabin-IPV | Vaccine | — | — |
| Subject | bivalent oral poliovirus vaccine | Vaccine | — | — |